Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | GPR6 | P46095 | 4/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596047 | 0.94 | SIGMAR1 (0.40) | LMNASMN1; SMN2SIGMAR1HRH2GPR6 | |
| SCHEMBL3588625 | 0.94 | HRH2 (0.37) | SIGMAR1HRH2GPR6 | |
| SCHEMBL3585685 | 0.94 | KMT2A (0.41) | SIGMAR1HRH2GPR6 | |
| SCHEMBL3599682 | 0.94 | CHRM4 (0.36) | ALDH1A1SIGMAR1HRH2GPR6CYSLTR2 | |
| SCHEMBL3593937 | 0.94 | KDM1A (0.37) | KDM1ASIGMAR1HRH2GPR6 | |
| SCHEMBL14160068 | 0.93 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTSMN1; SMN2TP53 | |
| SCHEMBL3588718 | 0.93 | SIGMAR1 (0.35) | ALDH1A1LMNASIGMAR1HRH2GPR6 | |
| SCHEMBL3593372 | 0.91 | MEN1 (0.40) | SIGMAR1HRH2 | |
| SCHEMBL3586599 | 0.91 | PRKAA2 (0.38) | SIGMAR1HRH2GPR6 | |
| SCHEMBL3587512 | 0.91 | GPR6 (0.36) | KDM1ASIGMAR1HRH2GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | ALDH1A1 4118/4885LMNA 4335/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.